Cover Image
市場調查報告書

Poxel SA:產品平台分析

Poxel SA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 251708
出版日期 內容資訊 英文 30 Pages
訂單完成後即時交付
價格
Back to Top
Poxel SA:產品平台分析 Poxel SA - Product Pipeline Review - 2015
出版日期: 2015年11月25日 內容資訊: 英文 30 Pages
簡介

Poxel SA 是專門開發第二型糖尿病等代謝疾病治療藥的生物製藥公司。該公司的口服藥imeglimin可望有改善第二型糖尿病患者的血糖管理效果。

本報告提供Poxel SA的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Poxel SA的基本資料

Poxel SA概要

  • 主要資訊
  • 企業資料

Poxel SA:R&D概要

  • 主要的治療範圍

Poxel SA:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Poxel SA:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Poxel SA:藥物簡介

  • imeglimin
  • PXL-770
  • Small Molecule to Agonize GLP-1 for Type 2 Diabetes
  • Small Molecule to Activate Glucokinase for Type 2 Diabetes
  • Small Molecule to Agonize Farnesoid X Receptor for Metabolic Disorders, Cardiovascular and Gastrointestinal Disorders
  • Small Molecule to Inhibit 11 Beta-Hydroxysteroid Dehydrogenase for Type 2 Diabetes

Poxel SA:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Poxel SA:最近的開發平台趨勢

Poxel SA:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07808CDB

Summary

Global Markets Direct's, 'Poxel SA - Product Pipeline Review - 2015', provides an overview of the Poxel SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Poxel SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Poxel SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Poxel SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Poxel SA's pipeline products

Reasons to buy

  • Evaluate Poxel SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Poxel SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Poxel SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Poxel SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Poxel SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Poxel SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Poxel SA Snapshot
    • Poxel SA Overview
    • Key Information
    • Key Facts
  • Poxel SA - Research and Development Overview
    • Key Therapeutic Areas
  • Poxel SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Poxel SA - Pipeline Products Glance
    • Poxel SA - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Poxel SA - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • Poxel SA - Drug Profiles
    • imeglimin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PXL-770
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate Glucokinase for Type 2 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize Farnesoid X Receptor for Type 2 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize GLP-1 for Type 2 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit 11 Beta-Hydroxysteroid Dehydrogenase for Type 2 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Poxel SA - Pipeline Analysis
    • Poxel SA - Pipeline Products by Target
    • Poxel SA - Pipeline Products by Route of Administration
    • Poxel SA - Pipeline Products by Molecule Type
    • Poxel SA - Pipeline Products by Mechanism of Action
  • Poxel SA - Recent Pipeline Updates
  • Poxel SA - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Poxel SA, Key Information
  • Poxel SA, Key Facts
  • Poxel SA - Pipeline by Indication, 2015
  • Poxel SA - Pipeline by Stage of Development, 2015
  • Poxel SA - Monotherapy Products in Pipeline, 2015
  • Poxel SA - Out-Licensed Products in Pipeline, 2015
  • Poxel SA - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Poxel SA - Phase II, 2015
  • Poxel SA - Phase I, 2015
  • Poxel SA - Discovery, 2015
  • Poxel SA - Pipeline by Target, 2015
  • Poxel SA - Pipeline by Route of Administration, 2015
  • Poxel SA - Pipeline by Molecule Type, 2015
  • Poxel SA - Pipeline Products by Mechanism of Action, 2015
  • Poxel SA - Recent Pipeline Updates, 2015

List of Figures

  • Poxel SA - Pipeline by Stage of Development, 2015
  • Poxel SA - Monotherapy Products in Pipeline, 2015
  • Poxel SA - Pipeline by Top 10 Target, 2015
  • Poxel SA - Pipeline by Top 10 Route of Administration, 2015
  • Poxel SA - Pipeline by Top 10 Molecule Type, 2015
  • Poxel SA - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top